Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

CiteULike is a free service for managing and discovering scholarly references - click here to get started.

Sign In to gain access to subscriptions and/or personal tools.
Medical Decision Making
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Chang, R. W.
Right arrow Articles by Fineberg, H. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chang, R. W.
Right arrow Articles by Fineberg, H. V.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Risk-Benefit Considerations in the Management of Polymyalgia Rheumatica

Rowland W. Chang, M.D., M.P.H.

Harvey V. Fineberg, M.D., Ph.D.

Management of the polymyalgia rheumatica syndrome (PMR) is controversial. Grat ifying symptomatic response usually occurs after treatment with nonsteroidal anti inflammatory drugs or low doses of corticosteroids. However, some PMR patients are at risk of sudden blindness from an associated disease, giant cell arteritis (GCA). Blindness can be prevented by using higher and more toxic doses of corticosteroids. Temporal artery biopsy can be an aid in diagnosis, though it is not a completely sen sitive test for GCA.

This study employs decision analysis and derived risk-benefit ratios (equivalent to utility ratios) to evaluate five possible PMR management strategies. The incremental risk-benefit analysis provides a means for weighing intangible trade-offs without a formal utility analysis. Given base case assumptions derived from the literature, empirical treatment with high-dose steroids cannot be justified for PMR patients who have no cranial arteritic symptoms, because the acceptable risk-benefit ratio associated with this strategy is more than 90 cases of severe medication side effects per case of monocular blindness averted. (Med Decis Making 3:459-475, 1983)

Medical Decision Making, Vol. 3, No. 4, 459-475 (1983)
DOI: 10.1177/0272989X8300300404
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 JAMAHome page
W. N. Roberts, M. H. Liang, and S. H. Stern
Colchicine in Acute Gout: Reassessment of Risks and Benefits
JAMA, April 10, 1987; 257(14): 1920 - 1922.
[Abstract] [PDF]

Home page
 ANN INTERN MEDHome page
J. P. KASSIRER, A. J. MOSKOWITZ, J. LAU, and S. G. PAUKER
Decision Analysis: A Progress Report
Ann Intern Med, February 1, 1987; 106(2): 275 - 291.
[Abstract] [PDF]

Home page
 Arch Intern MedHome page
M. A. Papadakis and N. D. Schwartz
Temporal Arteritis After Normalization of Erythrocyte Sedimentation Rate in Polymyalgia Rheumatica
Arch Intern Med, November 1, 1986; 146(11): 2283 - 2284.
[Abstract] [PDF]

Home page
 ANN INTERN MEDHome page
H. C. SOX Jr. and M. H. LIANG
Diagnostic Decision: The Erythrocyte Sedimentation Rate * Guidelines for Rational Use
Ann Intern Med, April 1, 1986; 104(4): 515 - 523.
[Abstract] [PDF]